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ABSTRACT
all bladder cancer is the most aggressive 
cancer and commonest malignant tumor of the Gbiliary tract worldwide with the shortest 
1,2
median survival from the time of diagnosis . The 
incidence increases with age, commoner in whites than 
blacks and women are 2 to 6 times more affected than 
2
men . The aggressive biologic behavior and lack of 
sensitive screening tests for early detection are partly 
3
responsible for the poor prognosis of this condition .
Surgical resection is the only chance for a complete 
cure; however, only 10% of patients are candidates for 
2
curative surgery at the initial presentation . Factors like 
anatomical complications of the portobiliary hepatic 
system, the morbidity/mortality associated with liver 
resection and risks of tumor spread due to 
manipulation even confer a high mortality rate among 
those suitable for resection4. Furthermore, recurrence 
rates are high among those that undergo surgical 
2
resection .
This paper seeks to review the current concepts and key 
issues in the diagnosis and management of gallbladder 
cancer.
METHODOLOGY
A systematic review of published literature was done 
using search Google Search Engine, Highwire press 
and Springer Link selected papers were taken and 
books from author's collection used for further 
reference. 
INTRODUCTION
INTRODUCTION:  Gall bladder cancer is the most aggressive cancer and the commonest malignant tumor of 
the biliary tract worldwide. The incidence increases with age and women are more commonly affected. Surgical 
resection is the only chance for complete cure, however only 10% of patients are candidates for curative surgery at 
initial presentation.
OBJECTIVE:  To review the current concepts and key issues in the diagnosis and management of gallbladder 
cancer.
METHODOLOGY:  A systematic review of published literature was done using search Google Search Engine, 
Highwire press and Springer Link selected papers were taken and books from author's collection used for further 
reference.
RESULTS:  The risk factors of gallbladder cancer include race (like India), cholelithiasis, polyps, pancreatico-biliary 
maljunction anomalies, chronic inflammation, exposures to heavy metals and chemicals and infections (e.g. liver 
flukes). It may present as mass lesion, localized wall thickening or polypoid growth. Adenocarcinoma is the 
commonest histological type. The clinical presentation is divided into 5 syndromes namely acute cholecystitis, 
chronic cholecystitis, biliary tract disease, non specific symptomatology and symptoms related to metastatic 
disease. Complete surgical treatment is the only curative treatment for gallbladder cancer but only a few cases are 
seen at this curative stage. 
CONCLUSION: Gallbladder cancer is relatively uncommon with high mortality rate. Risk factors include 
advance age, female gender, cholelithiasis, porcelain gallbladder, gallbladder polyps, congenital biliary cysts, chronic 
infection and smoking. Most are discovered incidentally at routine cholecystectomy or present at advance stage of 
the disease. Surgery is the only curative therapy for gallbladder cancer and the extent is dependent on the TNM 
stage. However, at diagnosis, only 10% of patients are candidates for curative surgery.
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Polyps at risk of malignant transformation are typically 
rapidly growing and ? 10mm in size and 
solitary/sessile polyps in patients ≥50years with 
6
gallstones .
General concensus guidelines for removal of 
gallbladder polyps ?  10mm in size, patients ?  60 years, 
increasing growth on serial imaging and/or presence 
11
of gallstones . A study suggests that polyps ?  2cm can 
12
be followed by serial ultrasound every 3-6 months . 
Conversely, other authors point out that up to 40% of 
malignant gallbladder polyps may be ?  1cm in size and 
thus patients with a polyp of 5-10mm should not be 
13
excluded from investigation .
PANCREATICOBILIARY MALJUNCTION 
ANOMALIES (PBM): This is a congenital anomaly in 
which there is an abnormal union of the biliary and 
pancreatic ducts located outside the duodenal wall in 
which a sphincter is not present. It allows pancreatic 
fluid to reflux into the biliary system causing 
inflammation and genetic alterations, leading to 
increased cellular proliferation resulting in 
hyperplasia, dysplasia and then carcinoma. About 10% 
6
of patients with gallbladder cancer have this anomaly . 
These patients also have a higher frequency of K-ras 
14
mutations .
Among non PBM patients, pancreaticoduodenal reflux 
may occur secondary to a long common channel or 
high confluence of pancreaticobiliary ducts. A channel 
length of ?  8mm is more frequent in patients with 
5
gallbladder cancer (3%) . The pancreaticobiliary reflux 
causes severe irritation of the gallbladder mucosa.
CHRONIC INFLAMMATION: This is considered a 
major factor in carcinogenesis causing DNA damage, 
tissue proliferation and cytokine and growth factor 
release. It also causes deposition of calcium within the 
gallbladder wall, making the gallbladder to develop a 
bluish hue and becoming fragile-the “procellain 
gallbladder”. Less than 1% of gallbladder specimens 
demonstrate this change, but in about 25% of cases, 
11
associated with gallbladder cancer . Only specimens 
with stapled calcification on imaging are considered 
potentially premalignant as transmural calcification is 
6
less likely to develop malignancy .
Chronic inflammatory diseases such as primary 
sclerosing cholangitis are reported to be associated 
with a higher incidence of gallbladder cancer. 
Therefore, it is recommended that patients with 
primary sclerosing cholangitis should undergo annual 
gallbladder surveillance screening with ultrasound for 
6
the detection of abnormal lesions .
RESULTS
RISK FACTORS
RACIAL FACTORS: There is geographical variability 
in the prevalence of gallbladder cancer worldwide. 
Some areas with high incidence include Delhi, India 
(21.5/100000), Lapaz, Bolivia (15.5/100000), South 
Karachi, Pakistan (15.8/100000), Quito, Ecuador 
1
(12.9/100000) . Low incidence of 0.4-0.8/100000 in men 
and 0.6-1.4/100000 in women have been reported in the 
western world (United States of America, United 
5
Kingdom, Canada, Australia and New Zealand) .
Environmental exposures and regional genetic 
predisposition to carcinogenesis have been described 
6
as reasons for this geographical variability . This 
variability has also been attributed to dietary factors, 
with diets high in calories, carbohydrates, red meats, 
oils and red chili pepper conferring a higher risk while 
intake of green leafy vegetables and fruits may be 
7
protective . In keeping with this observation, obesity is 
a well recognized risk factor for the development of 
6,8
gallbladder cancer . For each 5 point increase in body 
mass index, the relative risk of developing gallbladder 
6,8
cancer increases by 1.59 for women and 1.09 for men
CHOLELITHIASIS: Gall stone is the most important 
risk factor for the development of gallbladder cancer 
with an 8.3 times higher risk than the general 
7,10
population . The percentage of gallbladder cancer 
patients with a history of cholelithiasis is about 70-
7,10
90% . Larger stones portend a greater risk, with stones 
? 3cm being 9.2-10.1 times greater than stones ? 1cm1. 
This increased risk is most likely attributable to greater 
local epithelial irritation. The exact mechanism 
whereby cholelithiasis predisposes to gallbladder 
cancer remains debatable.
Gallbladder cancer has been discovered incidentally in 
0.5-1.5% of patients who undergo cholecystectomy for 
1
presumed cholelithiasis . Autopsy studies have 
revealed a 1-2% incidence of gallbladder cancer in 
10
patients with cholelithiasis .
GALLBLADDER POLYPS: Nearly 5% of all adults 
have gallbladder polyps, but majority are 
pseudopolyps with no neoplastic potential: 
cholesterolosis (60% of gallbladder polyps), 
6
adenomyosis (25%) or inflammatory (10%) . Other 
potential gallbladder polyps include non neoplastic 
(hyperplastic and inflammatory) and neoplastic polyps 
(adenomas, leiomyomas, fibromas and lipomas). 
Benign adenomas, constituting 4% of all gallbladder 
polyps, play an unclear role in neoplastic 
transformation; however, the absence of adenoma 
remnants in mucosa adjacent to adenocarcinoma 
suggests these tumors may not play a role in 
6
carcinogenesis in all cases .




Immunohistochemistry shows that these tumors are 
positive for cytokeratin 7 (CK 7) with focal expression 
of carcinoembryonic monoclonal antibody (CEA-M), 
1 8
C A  1 9 - 9 ,  M U C 1 ,  B 7 2 - 3  a n d  M U C S A C .
Spread of gallbladder cancer occurs via 4 routes:
A) Local invasion of the liver (segments IV and V) or 
other nearby structures i.e bile duct, duodenum, colon, 
1,10
parietal wall and/or abdominal visceras . Invasion of 
the liver is the most common form of direct local spread 
because of the absence of serosa where the gallbladder 
14,19
attaches to the liver .
B) Lymphatic dissemination  C) Peritoneal spread 
and  D) Haematological spread.
A number of staging systems have been described for 
gallbladder cancer including Nevin's staging system, 
the Japanese Biliary Surgical Society staging 
systemand the Tumor Node Metastasis (TNM) staging 
system of the American Joint Committee on Cancer.
20
TABLE 1- TNM STAGING
T groups for gallbladder cancer
TX: The primary tumor's extent cannot be assessed.
T0: There is no evidence of primary tumor.
Tis: Cancer cells are only found in the epithelium.
T1: The tumor has grown into the lamina propria or 
the muscle layer (muscularis).
T1a: Tumor has grown into lamina propria.
T1b: Tumor has grown into the muscularis.
T2: The tumor has grown into perimuscular fibrous 
tissue.
T3: The tumor has grown through the serosa and/or it 
has grown directly into the liver and/or a nearby 
structure such as stomach, duodenum, colon, pancreas 
or bile ducts.
T4: The tumor has grown into one of the main blood 
vessels leading into the liver (portal vein or hepatic 
artery) or it has grown into 2 or more structures outside 
the liver.
N groups for gallbladder cancer
NX: Regional lymph nodes cannot be assessed.
N0: The cancer has not spread to regional lymph nodes.
N1: The cancer has spread to regional  lymph nodes 
such as those along the cystic duct, common bile duct, 
hepatic artery, and portal vein.
N2: Metastasis to the peri aortic, pericaval, superior 
mesenteric artery and/or celiac artery lymph nodes.
M groups for gallbladder cancer
M0: No metastasis
M1: Presence of metastasis
EXPOSURES: Many substances including heavy 
metals and radon have been thought to increase 
gallbladder cancer. Patients with gallbladder cancer 
have been shown to have low levels of selenium and 
zinc (which are anti oxidants) and higher levels of 
copper, lead, cadmium, chromium and nickel (well 
recognized carcinogens) in serum and bile compared to 
7,15
patients with cholelithiasis . Workers in oil, paper, 
chemical, shoe, textile and cellulose acetate fiber 
manufacturing have an increased risk of developing 
gallbladder cancer. Tobacco, methyldopa and 
isoniazid may increase the risk of gallbladder cancer 
while risk associated with intake of oral contraceptives 
7,15
remain controversial .
INFECTIONS: Liver flukes particularly Clonochis 
sinesis and Opisthorchis viverrini have been 
6
implicated in gallbladder cancer . An association 
between Helicobacter infection of the bile and 
gallbladder carcinogenesis may be related to bacteria 
induced degradation of bile acid; however, precise 
9
mechanisms remain poorly understood . Chronic 
bacteria cholangitis usually due to Salmonella and 
Helicobacter increases the risk of biliary tree 
malignancy. The microorganisms degrade bile 
constituents by hydrolyzing bile salts and forming 
carcinogens. Chronic typhoid carrier status is thus a 
significant risk factor, with 6% of carriers developing 
6
gallbladder cancer (a 12 times increased risk) .
PATHOLOGY
Gallbladder cancer may arise in the fundus (60%), body 
16
(30%) or neck (10%) . The development of gallbladder 
carcinoma occurs over a span of 5-15 years, with tissue 
alterations including metaplasia, dysplasia, carcinoma 
6
in situ and invasive cancer .
Gallbladder cancer may present as a mass lesion, 
localized wall thickening with induration of the wall or 
11
polyposis growth . Obstruction of the neck and/or 
cystic duct may cause distension or collapse of the 
gallbladder; neoplasms in the body may constrict the 
11
lateral wall resulting in an hour-glass deformity . 
These lesions are typically greyish-white in colour; 
however, mucinous and signet ring lesions have a 
gelatinous cut surface.
Adenocarcinoma is the commonest histological type, 
accounting for 98% of all gallbladder tumors, two-
thirds of which are moderately/poorly differentiated 
while the remaining common histological variants 
include papillary, mucinous, squamous and 
6
adenosquamous sub types . Other rare types of 
gallbladder cancer include carcinosarcoma, small cell 
carcinoma, lymphoma, signet ring cell-type tumors 
17
and metastasis . Tumors may contain more than one 
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Ultrasound may also stage the disease defining the 
extent of biliary tree involvement and confirming the 
presence hepatic, arterial or portal vein invasion.
ENDOSCOPIC ULTRASOUND: It's currently the 
definitive imaging modality staging of gallbladder 
cancer, allowing the precise imaging and acquisition of 
fine needle aspiration (FNA) biopsy.
COMPUTERIZED TOMOGRAPHY (CT) SCAN: 
This is the most common evaluative imaging in 
gallbladder cancer and its utilization has been 
26
increasing over time . It is useful in diagnosis and 
staging and can detect liver or porta hepatis invasion, 
lymphadenopathy and involvement of adjacent 
organs. The 4 patterns of gallbladder cancer that have 
been described on CT scan include a polypoid mass 
within the gallbladder lumen, focal wall thickening, 
diffuse wall thickening and a mass replacing the 
11
gallbladder .
E N D O S C O P I C  R E T R O G R A D E  
CHOLANGIOPANCREATICOGRAPHY (ERCP): It 
m a y  d e m o n s t r a t e  a n o m a l o u s  j u n c t i o n  o f  
pancreaticobiliary ducts and allows for the collection of 
bile samples, brush cytology and/or intralesional 
10
biopsy .
MAGNETIC RESONANCE IMAGING (MRI), 
MAGNETIC RESONANCE ANGIOGRAPHY 
( M R A )  A N D  M A G N E T I C  R E S O N A N C E  
CHOLANGIOPANCREATICOGRAPHY (MRCP): 
Combination of these 3 is useful in detecting vascular 
invasion, biliary tree involvement, liver invasion and 
9
lymph node involvement . MRI has been shown to be 
superior to CT scan for differentiating T1a lesions from 
T1b or greater and as such may be useful in pre 
27
operative management planning .
F L U O R O D E O X Y G L U C O S E - P O S I T R O N  
E M I S S I O N  T O M O G R A P H Y  ( F D G - P E T )  
SCANNING: This may be useful in detecting 
ambiguous primary lesions and residual disease after 
cholecystectomy.
PERCUTANEOUS APPROACHES: Image (US or CT) 
guided FNA biopsy has the potential for a diagnostic 
10
accuracy of 80-90% . False negative results of 11-41% 
may be attributed to incorrect sampling, necrosis or 
fibrosis.
LAPAROSCOPY: Staging laparoscopy is often helpful 
to assess for peritoneal spread or discontigous liver 
disease. Weber et alreported that unresectable disease 
was identified in 48% of their study patients by 
laparoscopy, thereby, preventing unnecessary 
9
morbidity with open laparotomy .
Stage grouping
Stage 0: Tis,N0,M0
Stage I:  T1,N0,M0
Stage II: T2,N0,M0
Stage IIIA: T3,N0,M0
Stage IIIB: T1 to T3, N1,MO
Stage IVA: T4,N0,M0
Stage IVB: Any T, N2,M0 or any T, any N M1
CLINICAL PRESENTATION
The symptoms of gallbladder cancer are relatively non 
specific which in part accounts for the often delayed 
diagnosis.
21
The presentation can be divided into 5 syndromes .
ACUTE CHOLECYSTITIS: Cancer incidence of 6-8% 
has been reported in elderly patients with acute 
cholelithiasis especially when associated with 
22
abnormal liver enzymes .
CHRONIC CHOLECYSTITIS: Recurrent cholecystitis 
in patients over age 50with known gallstone disease 
23
should raise suspicion for gallbladder cancer .
BILIARY TRACT DISEASE: Symptoms of biliary 
obstruction such as jaundice, right upper quadrant 
pain, nausea, vomiting and in later stages, pruritus are 
often associated with unresectable disease. Mirizzi 
syndrome has been associated with a high incidence of 
24
gallbladder cancer .
NON SPECIFIC SYMPTOMATOLOGY: Anorexia, 
weight loss and generalized weakness are common 
symptoms related to gallbladder cancer. Symptoms 
can also result from local complications such as fistula 
formation, invasion of adjacent organ presenting with 
haemobilia, gastrointestinal bleeding and intestinal 
obstruction. The presence of a palpable right upper 
25
quadrant mass indicates unresectability in most cases .
SYMPTOMS AND SIGNS RELATED TO 
METASTATIC DISEASE:  Inc lude asc i tes ,  
hepatomegaly and paraneoplastic syndromes such as 
acanthosis nigricans
                                                               
INVESTIGATIONS
ULTRASOUND (US): Most often, this is the initial 
diagnostic study when the gallbladder is diseased. 
Gallbladder cancer may appear as a mass replacing or 
invading the gallbladder, intraluminal growth/polyp 
or an assymetric gallbladder wall thickening. In 
advanced disease, the sensitivity and specificity are 85 
and 80% respectively; however, in early disease, it fails 
to detect any abnormality, particularly when the tumor 
9
is flat or sessile and is associated with cholelithiasis . 
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fluoropyrimidine or gemcitabine chemotherapy in 
patients with ?  T1N0 gallbladder cancer  following 
curative surgery.
LOCALLY ADVANCED UNRESECTABLE 
METASTATIC GALLBLADDER CANCER: The 
options include fluoropyrimidinechemoradiation or 
gemcitabine based chemotherapy (such as 
g e m c i t a b i n e / c i s p l a t i n  c o m b i n a t i o n )  o r  
fluoropyrimidine based chemotherapy. Tumor control 
31
is rarely achieved with external beam radiation alone . 
However, it is not known if chemoradiation therapy is 
superior to chemotherapy alone.
METASTATIC GALLBLADDER CANCER: Systemic 
chemotherapy has shown significant but modest 
survival benefit in the management of advanced 
gallbladder cancer. In a randomized trial compared 
systemic chemotherapy of gemcitabine plus 
oxaloplatin or 5 fluorouracil plus leucovorin versus 
best supportive care alone in 81 patients with 
unresectable gallbladder cancer, median overall 
s u r v i v a l  i n  b e s t  s u p p o r t i v e  c a r e  a n d  5  
fluorouracil/leucovorin group was 4.5 and 4.6 months 
respectively versus 9.5 months in gemcitabine plus 
32
oxaloplatin group . 
CONCLUSION
Gallbladder cancer is relatively uncommon with high 
mortality rate. Risk factors include advance age, female 
gender, cholelithiasis, porcelain gallbladder, 
gallbladder polyps, congenital biliary cysts, chronic 
infection and smoking. Most are discovered 
incidentally at routine cholecystectomy or present at 
advance stage of the disease. Surgery is the only 
curative therapy for gallbladder cancer and the extent 
is dependent on the TNM stage. However, at diagnosis, 
only 10% of patients are candidates for curative 
surgery.
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